参芪扶正液辅助治疗重症急性胰腺炎的临床效果  

Clinical Effect of Shenqi Fuzheng Liquid in Adjuvant Treatment of Severe Acute Pancreatitis

作　　者：徐霞 范辉[1] 王小红 XU Xia;FAN Hui;WANG Xiaohong(Department of Gastroenterology,the Second People's Hospital of Nantong City,Nantong 226002,China;不详)

机构地区：[1]南通市第二人民医院消化内科,江苏南通226002 [2]南京鼓楼医院集团仪征医院消化内科,江苏仪征211900

出　　处：《中国医学创新》2024年第27期10-14,共5页Medical Innovation of China

基　　金：江苏省中医药科技发展计划项目(YB2020088)。

摘　　要：目的:探究参芪扶正液辅助治疗重症急性胰腺炎的临床效果。方法:前瞻性选择2019年1月—2022年12月74例在南通市第二人民医院消化内科重症监护病房(GICU)进行治疗的74例重症急性胰腺炎患者,按照随机数字表法分为观察组(37例)和对照组(37例)。两组患者均给予液体复苏、抑酸、抑制胰腺分泌、抑制胰酶活性及抗感染治疗,同时给予早期肠内营养。观察组另外给予参芪扶正液治疗。比较两组治疗前和治疗14 d后的T淋巴细胞亚群、肠源性感染指标浓度、入住ICU时间、并发症发生率。结果:治疗前,两组患者的细胞免疫功能差异均无统计学意义(P>0.05);治疗后,观察组CD3^(+)为(73.02±6.49)%、CD4^(+)为(57.09±5.04)%,均显著高于对照组的CD3^(+)[(64.19±5.86)%]、CD4^(+)[(47.62±4.35)%];CD4^(+)/CD8^(+)为(2.45±0.57),显著高于对照组的(2.11±0.62),差异均有统计学意义(P<0.05)。治疗14 d后,观察组C反应蛋白(CRP)、降钙素原(PCT)、内毒素(ET)水平均显著低于对照组,观察组呼吸衰竭、胰腺感染、MODS的发生率均明显低于对照组,以及入住ICU时间短于对照组,差异均有统计学意义(P<0.05)。两组肾衰竭、肺炎发生率比较差异均无统计学意义(P>0.05)。结论:给予重症急性胰腺炎患者参芪扶正液能较好地改善患者细胞免疫功能,降低肠源性细菌引发的感染率和各种并发症的发生率,具有较好的应用价值。Objective:To investigate the clinical effect of Shenqi Fuzheng Liquid in adjuvant treatment of severe acute pancreatitis.Method:A total of 74 patients with severe acute pancreatitis admitted to the Gastroenterological Intensive Care Unit(GICU)of the Second People's Hospital of Nantong City between January 2019 and December 2022 were selected and divided into the observation group(37 cases)and the control group(37 cases)using the random number table method.Both groups of patients were given fluid resuscitation,acid suppression,inhibition of pancreatic secretion,inhibition of pancreatic enzyme activity and anti-infective treatment,as well as early enteral nutrition.The observation group was additionally given Shenqi Fuzheng Liquid for adjuvant treatment.The T lymphocyte subpopulation,enterogenic infection index concentration before treatment and after 14 days of treatment,ICU length of stay,and complication rate were compared between the two groups.Result:Before treatment,there were no statistically significant differences in cellular immune function between the two groups of patients(P>0.05);after treatment,the level of CD3^(+)was(73.02±6.49)%and the level of CD4^(+)was(57.09±5.04)%in the observation group,which were significantly higher than CD3^(+)[(64.19±5.86)%]and CD4^(+)[(47.62±4.35)%]in the control group;the CD4^(+)/CD8^(+)was(2.45±0.57)in the observation group,which was significantly higher than(2.11±0.62)in the control group,the differences were statistically significant(P<0.05).After 14 days of treatment,the levels of C reactive protein(CRP),procalcitonin(PCT)and endotoxin(ET)in the observation group were significantly lower than those in the control group,the incidence rates of respiratory failure,pancreatic infection and MODS in the observation group were significantly lower than those in the control group,and the ICU admission time in the observation group was shorter than that in the control group,with statistically significant differences(P<0.05).There were no statistically significant differen

关 键 词：参芪扶正液 重症急性胰腺炎 T淋巴细胞 C反应蛋白 内毒素 

分 类 号：R576[医药卫生—消化系统]